Oct. 27 at 4:59 PM
$IOVA Folks, what do you think? 🤔 IMO, it could be possible that the ESMO and SITC presentations are calculated to signal what’s coming. ESMO’s focus was on Amtagvi survival data (17-26% cure rates, 89-month lifetime OS) targets payers, while SITC’s focus is on efficacy - rash-efficacy link empowers clinicians, priming NSCLC/endometrial catalysts.
ESMO (survival data for payers) + SITC (rash-efficacy for clinicians) = primed monster data/growth.
Then the other items:
$100M+ annual savings (announced Aug 7, via Q4 workforce/R&D cuts) will be in full effect soon/MFG efficiency gains to help improve margins/InspiroGene by McKesson partnership; plus IP moat (patents to 2044) secure TIL manufacturing.
Long-term, If (a huge IF) catalysts hit, profitability could arrive by Q4 27 with
$50M+ net income on expansions. Sustained profitability in 28 with
$200M annual profits. A lot could go wrong, but it’s possible. 🤷♂️